Coloplast reports solid Q3 with 6.6% organic sales growth

Coloplast (CSE:COLOb) reported in-line third-quarter organic sales growth of 6.6% and a slightly better-than-expected EBIT margin of 27.5%, driven by strong performance across most segments. Despite Wound Care underperforming due to a product recall, the medical device company maintained its full-year guidance for approximately 7% organic sales growth and a 27-28% EBIT margin, incorporating the recall's DKK80 million impact. Concurrently, Coloplast announced an immediate organizational restructuring into Chronic Care and Acute Care units, a strategic move to optimize operations and capitalize on momentum in other areas.

Analysis

Coloplast reported a solid third quarter, with organic sales growth of 6.6% meeting consensus estimates and an EBIT margin of 27.5% slightly exceeding expectations of 27.3%. This performance was driven by robust growth in its core segments, including Continence Care (8%), Voice & Respiratory Care (9%), and Ostomy (6%). However, this strength was partially offset by significant underperformance in Wound Care, which grew only 4% against a 10% consensus forecast due to a product recall in China that created a DKK20 million negative sales impact. Additionally, Kerecis growth decelerated to 17% because of operational delays. Despite these headwinds, Coloplast reaffirmed its full-year 2024/25 guidance for approximately 7% organic sales growth and a 27-28% EBIT margin, signaling that it expects strong momentum in other areas to absorb the DKK80 million total projected impact from the recall. Concurrently, the company announced an immediate strategic restructuring into two units, Chronic Care and Acute Care, a move designed to sharpen operational focus on its distinct business lines.

Key Decisions for Investors

• Given that Coloplast maintained its full-year guidance despite absorbing an DKK80 million recall impact, the results signal underlying stability, suggesting the stock remains a hold for investors comfortable with the current outlook.
• Investors should closely monitor the performance of the newly formed Acute Care division, specifically looking for a resolution to the Wound Care supply issues and a re-acceleration in Kerecis's growth trajectory.
• The announced organizational restructuring is a key development to watch, as its successful implementation could unlock greater efficiency and represents a potential catalyst for future performance.